Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia

Platzbecker, Uwe; Germing, Ulrich; Schäkel, Ulrike; Illmer, Thomas; Soucek, Silke; Schaich, Markus; Ehninger, Gerhard; Thiede, Christian

doi:10.1038/sj.leu.2404399

Cited by 4 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study detected an homozygous G-CSFR Lys785Lys genotype in a patient with secondary AML following high-risk MDS, but since DNA from non-hematopoietic cells was not studied, it remained unclear whether this base change represented a polymorphism or an acquired mutation [158]. However, analysis of another cohort of patients with MDS and AML with multilineage dysplasia (MD) did not support the relevant increased prevalence of the G-CSFR Glu785Lys polymorphism in those patients compared to the general population [159].…”

Section: Identification Of Mutations and Polymorphisms In G-csfrmentioning

confidence: 99%

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization

Crea

Giovannetti

Zinzani

et al. 2009

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Section: Identification Of Mutations and Polymorphisms In G-csfrmentioning

confidence: 99%

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization

Crea

Giovannetti

Zinzani

et al. 2009

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

Graft-versus-Host disease Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy: Results of the EVTAC Trial

Platzbecker

Bonin

Goekkurt

et al. 2009

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

A calcineurin inhibitor combined with methotrexate is the standard prophylaxis for graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Everolimus, a derivative of sirolimus, seems to mediate antileukemia effects. We report on a combination of everolimus and tacrolimus in 24 patients (median age, 62 years) with either myelodysplastic syndrome (MDS; n = 17) or acute myeloid leukemia (AML; n = 7) undergoing intensive conditioning followed by HSCT from related (n = 4) or unrelated (n = 20) donors. All patients engrafted, and only 1 patient experienced grade IV mucositis. Nine patients (37%) developed acute grade II-IV GVHD, and 11 of 17 evaluable patients (64%) developed chronic extensive GVHD. Transplantation-associated microangiopathy (TMA) occurred in 7 patients (29%), with 2 cases of acute renal failure. The study was terminated prematurely because an additional 6 patients (25%) developed sinusoidal obstruction syndrome (SOS), which was fatal in 2 cases. With a median follow-up of 26 months, the 2-year overall survival rate was 47%. Although this new combination appears to be effective as a prophylactic regimen for acute GVHD, the incidence of TMA and SOS is considerably higher than seen with other regimens.

show abstract

The pathogenesis of myelodysplastic syndromes (MDS)

Platzbecker

Meredyth-Stewart

Ehninger

2007

Cancer Treatment Reviews

View full text Add to dashboard Cite

Association with the single-nucleotide polymorphism (Glu785Lys) of the granulocyte colony-stimulating factor receptor with myelodysplastic syndromes and acute myeloid leukemia with multlineage dysplasia

Cited by 4 publications

References 3 publications

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization

Pharmacologic rationale for early G-CSF prophylaxis in cancer patients and role of pharmacogenetics in treatment optimization

Graft-versus-Host disease Prophylaxis with Everolimus and Tacrolimus Is Associated with a High Incidence of Sinusoidal Obstruction Syndrome and Microangiopathy: Results of the EVTAC Trial

The pathogenesis of myelodysplastic syndromes (MDS)

Contact Info

Product

Resources

About